Evaluation of dose reduction versus standard dosing for maintenance of remission in patients with spondyloarthritis and clinical remission with anti-TNF (REDES-TNF): Study protocol for a randomized controlled trial by Pontes, Caridad et al.
TRIALS
Pontes et al. Trials  (2015) 16:370 
DOI 10.1186/s13063-015-0828-5STUDY PROTOCOL Open AccessEvaluation of dose reduction versus standard
dosing for maintenance of remission in patients
with spondyloarthritis and clinical remission with
anti-TNF (REDES-TNF): study protocol for a
randomized controlled trial
Caridad Pontes1, Jordi Gratacós2*, Ferran Torres3, Cristina Avendaño4, Jesús Sanz5, Antoni Vallano6, Xavier Juanola7,
Eugenio de Miguel8, Raimon Sanmartí9 and Gonzalo Calvo10Abstract
Background: Dose reduction schedules of tumor necrosis factor antagonists (anti-TNF) as maintenance therapy in
patients with spondyloarthritis are used empirically in clinical practice, despite the lack of clinical trials providing
evidence for this practice.
Methods/Design: To address this issue the Spanish Society of Rheumatology (SER) and Spanish Society of Clinical
Pharmacology (SEFC) designed a 3-year multicenter, randomized, open-label, controlled clinical trial (2 years for
inclusion and 1 year of follow-up). The study is expected to include 190 patients with axial spondyloarthritis on
stable maintenance treatment (≥4 months) with any anti-TNF agent at doses recommended in the summary of
product characteristics. Patients will be randomized to either a dose reduction arm or maintenance of the dosing
regimen as per the official labelling recommendations. Randomization will be stratified according to the anti-TNF
agent received before study inclusion. Patient follow-up, visit schedule, and examinations will be maintained as per
normal clinical practice recommendations according to SER guidelines. The study aims to test the hypothesis of
noninferiority of the dose reduction strategy compared with standard treatment. The first patients were recruited in
July 2012, and study completion is scheduled for the end of April 2015.
Discussion: The REDES-TNF study is a pragmatic clinical trial that aims to provide evidence to support a medical
decision now made empirically. The study results may help inform clinical decisions relevant to both patients and
healthcare decision makers.
Trial registration: EudraCT 2011-005871-18 (21 December 2011)
Keywords: Spondyloarthritis/therapy, DMARDs (biologic), Disease Activity, Treatment* Correspondence: jgratacosmas@gmail.com
2Rheumatology Service, Hospital de Sabadell. Institut Universitari Parc Taulí,
Universitat Autònoma de Barcelona, 08208 Sabadell (Barcelona), Spain
Full list of author information is available at the end of the article
© 2015 Pontes et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
Pontes et al. Trials  (2015) 16:370 Page 2 of 12Background
Spondyloarthritis is a group of rheumatic diseases, in-
cluding ankylosing spondylitis, psoriatic arthritis, and
patients with the clinical features of spondyloarthritis ac-
cording to the European Group for the Study of Spondy-
loarthritis criteria [1] who do not fulfill criteria for a
defined spondyloarthritis and are classified as having un-
differentiated spondyloarthritis [2]. In recent years, new
Assessment of Spondyloarthritis International Society
(ASAS) classification criteria have classified spondyloar-
thritis as axial or peripheral, according to the clinical
pattern. The conditions share immunogenic, clinical,
and radiological characteristics, and the natural course
of the disease [2]. Diagnostic criteria differ between axial
[3] and peripheral disease [4]. The overall prevalence of
spondyloarthritis is equal to or even higher than that of
rheumatoid arthritis, with marked differences by race,
prevalence of HLA B27, and geographical area [5, 6].
Many patients with spondyloarthritis have disabling dis-
ease with joint deformities and/or ankylosis and im-
paired quality of life despite treatment [7, 8].
The treatment of ankylosing spondylitis and other
spondyloarthritis is mainly based on non-steroidal anti-
inflammatory drugs (NSAIDs) and physical therapy,
which have demonstrated efficacy, especially in the con-
trol of spinal symptoms. There is little evidence of the
efficacy of disease-modifying anti-rheumatic drugs
(DMARDs) in spondyloarthritis. In controlled studies,
sulfasalazine, methotrexate, and leflunomide have shown
modest efficacy on the peripheral manifestations of an-
kylosing spondylitis, but the utility of these drugs in
axial disease is unclear; therefore, DMARDs are not in-
cluded as an alternative treatment in patients with axial
spondyloarthropathies refractory to NSAIDs [9–12].
Significant numbers of patients with axial spondyloar-
thritis do not respond to NSAIDs; in these patients, the
clinical benefit of tumor necrosis factor antagonists
(anti-TNF) has been demonstrated in various clinical tri-
als [13]. Therefore, anti-TNF are now considered the
standard of care and are widely used in patients who do
not respond to NSAIDs, both in the acute phase and as
maintenance treatment, with sustained, prolonged clin-
ical remission obtained for months or years [14].
Safety concerns on the use of anti-TNF mainly derive
from their effects on the chronic suppression of the im-
mune response, which increases the risk of serious infec-
tion. It is unclear whether prolonged use may also
increase the occurrence of malignancies. These risks are
more pronounced with longer treatments, in frail popu-
lations such as the elderly, and in patients receiving high
doses [15–17]. While available clinical trials have shown
that these treatment regimens have a good benefit/risk
ratio, the optimal duration and most appropriate dose
for long-term treatment remain unclear.Several studies have evaluated the effect of the with-
drawal of anti-TNF in ankylosing spondylitis patients, and
all have reported disease reactivation in almost all patients
in the first months after treatment withdrawal [18–20].
Even so, it is reasonable to suggest that in patients in
stable remission, with no clinically evident inflammation
and potentially low or absent levels of inflammatory me-
diators, lower doses of anti-TNF may be sufficient to
block pro-inflammatory cytokines such as TNF-alpha;
thus, lower anti-TNF doses may represent a more rational
use of these drugs. Currently, various uncontrolled stud-
ies have reported anti-TNF dose in some patients de-
pending on the clinical status, and many rheumatologists
empirically apply anti-TNF dose reductions [19, 21–24].
A recent position paper by the Spanish Society of
Rheumatology and Spanish Society of Hospital Pharmacy
has recommended anti-TNF dose reduction in some pa-
tients, based on this partial evidence. [25]. However, in
patients showing persistent clinical remission over time,
no evidence from comparative studies exists on the effi-
cacy of maintaining disease remission and the safety of
using lower anti-TNF doses, either by administering
lower doses or by increasing dosing intervals. Current au-
thorized labelling of anti-TNF drugs recommends chronic
treatment with stable doses even when apparent disease
remission has been achieved [10].
This study is designed to answer a relevant clinical
question, considering that a large proportion of patients
with spondyloarthritis are chronically treated with anti-
TNF, and these patients are, on the one hand, at risk of
adverse effects secondary to prolonged treatment and,
on the other hand, require the use of relevant health re-
sources. The healthcare burden of anti-TNF treatment
acquisition, administration and monitoring is substantial
[26]. The present study is a joint initiative of the Spanish
Society of Clinical Pharmacology (SEFC) and Spanish
Society of Rheumatology (SER), and in particular, the
Spanish Group for the Study of Spondyloarthritis
(GRESSER), aimed at generating evidence to guide clin-
ical practice.
The main study hypothesis is that the use of reduced
anti-TNF doses is not inferior to the use of full doses in
patients with axial spondyloarthritis in persistent clinical
remission with anti-TNF, as assessed by the proportion
of patients who meet clinical remission defined by the
SER at one year [27].
Methods/Design
Study design
A prospective, multicenter, controlled, randomized open-
label study was designed. Patients with axial spondyloar-
thritis treated with anti-TNF for ≥20 weeks with sustained
clinical remission during the last ≥8 weeks will be in-
cluded. Patients will be randomized to receive a full anti-
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teristics or a reduced anti-TNF dose according to an
agreed-upon protocol. The study duration will be ap-
proximately 3 years (2 years recruitment and 1 year of
additional follow-up of last patient included). The study
design is summarized in Fig. 1.
Study objectives and main variables
The primary study objective is to assess, when considering
patients with axial spondyloarthritis who have achieved
sustained clinical remission with anti-TNF, whether the
proportion of patients reaching an acceptable therapeutic
goal after 1 year is greater than or equal in patients receiv-
ing reduced doses of anti-TNF to patients using standard
anti-TNF doses, according to the summary of product
characteristics. For this study, an acceptable therapeutic
goal will be BASDAI <4, physician global assessment <4
and patient <4 and axial night pain <4) [27]. The key main
secondary objective is to assess whether the proportion of
patients who remain in remission after one year (the ideal
therapeutic goal defined by BASDAI ≤ 2, physician global
assessment ≤ 2, and patient global assessment ≤ 2) [27] is
noninferior in patients receiving reduced doses of anti-
TNF to that of patients using standard anti-TNF doses;
this objective will require that the primary endpoint is
reached for formal assessment. The study outcome vari-
ables and definitions are listed in Table 1.
Other secondary objectives will include comparisons of
the effectiveness of each treatment regimen in terms of
clinical outcomes (ASDAS-C, ASAS response criteria,
ASAS partial remission, clinical assessment based on BAS-
DAI (overall and separately for the different clinical mani-
festations included in the BASDAI: global disease
assessment by the patient and physician, axial night pain
(visual analogue scales)) and assessment of analgesic and/
or NSAID requirements) and patient functionality (BASFI),
the time to study withdrawal due to treatment failure, and
quality of life (measured by ASQoL) (see Table 1 for defini-
tions) [27]. In addition, safety will be compared by assess-
ment of serious infections requiring systemic antibiotic
treatment and/or hospitalization, serious adverse reactionsFig. 1 Study designrequiring hospitalization and/or treatment withdrawal, and
a number of specific adverse effects (infusion reactions, in-
jection site reactions and other effects).
Additional exploratory objectives will include the in-
vestigation of clinical and/or biological factors related to
the therapeutic response (predictors of sustained re-
sponse or clinical reactivation) and of potential differ-
ences in the progression of structural damage between
treatment groups, based on blind evaluation of mSASSS
scores by blinded assessment of radiographs [28, 29].Randomization
After providing signed, informed consent, patients will be
screened and data introduced in the electronic case-report
form (eCRF), which will generate and provide an individual
patient screening code. Information on previous anti-TNF
treatment, clinical activity and other eligibility criteria will
be entered by investigators and automatically checked by
the eCRF for consistency and compliance with eligibility
criteria. Only when eligibility is confirmed will patients be
automatically randomized to one of the two study arms
and assigned a random identification code.
Stratified random allocation by previous anti-TNF medi-
cation (infliximab, etanercept, adalimumab, or golimu-
mab) will be made centrally, according to a randomization
list generated using SAS PROC PLAN v9.2 (SAS Institute
Inc., Cary, NC, USA) with a 1:1 ratio of assignment be-
tween arms in blocks of four elements. The randomization
list will be loaded into a separate module of the eCRF soft-
ware application. The module will automatically assign
the lowest sequential number available within the
randomization stratum; communicate the assigned strat-
egy (full or reduced dose) to the researcher; and keep an
auditable registry of the date, time and other variables re-
lated to stratification and treatment assignment.
Files and programs used for randomization will be de-
leted from the computer system of the statistics group
once loaded into the electronic database, and a sealed
copy will be retained by the Clinical Pharmacology Unit,
Hospital de Sabadell until database closure. Neither the
Table 1 Outcome variables and definitions
Outcomes Measures Time frame
Proportion of patients who are
at acceptable therapeutic goal
(SER)*
Acceptable therapeutic goal (SER)* 1 year post-randomization
(primary)
- BASDAI <4 End of study (secondary)
- Physician GA <4
- Patient GA <4
- Nocturnal axial pain <4
Proportion of patients who are
at ideal therapeutic goal (SER)*
Ideal therapeutic goal (SER)*: 1 year post-randomization (key secondary)
- BASDAI ≤2
- Physician GA ≤2 End of study
- Patient GA ≤2
Proportion of patients who are
in remission (ASDAS-C)
ASDAS-C <1.3 1 and 2 years post-randomization, End of study
Proportion of patients with disease
relapse (SER)*
Disease relapse (SER)* 1 and 2 years post-randomization, End of study
Time to clinical relapse (SER)* - BASDAI ≥4 During study follow-up
- Physician GA ≥4 AND one or more of 3:
- Patient GA ≥ 4
- Nocturnal axial pain≥ 4
- Increased CRP and/or ESR
Proportion of patients with
disease relapse (ASDAS-C)
ASDAS-C ≥2.1 1 and 2 years post-randomization, End of study
Time to clinical relapse
(ASDAS-C)*
During study follow-up
Proportion of patients with
clinical relapse
(BASDAI/Patient GA)
Clinical relapse 1 and 2 years post-randomization, End of study
Time to clinical relapse
(BASDAI/Patient GA)*
- BASDAI increase by 20 % or by 2/10 points AND During study follow-up
- Patient GA increased by 20 % or 2/10 points
Proportion of patients
withdrawn due to requirement
for changes in anti-TNF
treatment.
Unplanned change of the assigned anti-TNF
regimen decided by the investigator due to
lack of efficacy, safety issues or treatment-
related reasons.
End of study
NSAIDs use Dougados criteria (42) 1 and 2 years post-randomization, End of study
Patient function (BASFI) Change from baseline in the BASFI scores 1 and 2 years post-randomization, End of study
Ankylosing Spondylitis Quality
of Life (ASQoL)
Change from baseline in the ASQoL (Spanish
validated version of ASQoL (41))
1 and 2 years post-randomization, End of study
Proportion of patients with any
related severe adverse event
≥1 severe adverse events with causality
assessment at least possibly related to
anti-TNF
Time to related severe adverse
event
Number of days from randomization to first
symptom of a severe adverse event with
causality assessment at least possibly related to anti-TNF
Radiological progression mSASSS
*According to SER consensus [27]. SER: Sociedad Española de Reumatología (Spanish Society of Rheumatology). BASDAI: Bath Ankylosing Spondylitis Disease Activity
Index [49], which is calculated as {A + B + C + D + [(E + F) / 2]}/5 where A to E are 6 Visual Analog Scales (VAS) rated 0 (best) to 10 (worst) assessing (A) fatigue, (B)
axial skeletal pain, (C) peripheral joint pain, (D) pain on contact or pressure, (E) intensity of morning stiffness and (F) duration of morning stiffness. Physician GA:
Physician Global Assessment of disease activity by VAS rated 0 (best) to 10 (worst). Patient GA: Patient Global Assessment of disease activity by VAS rated 0 (best)
to 10 (worst). ASDAS-C: Ankylosing Spondylitis Disease Activity Score [50], which is calculated as (0.12 x back pain) + (0.06 x duration of morning stiffness) + (0.11 x
patient GA) + (0.07 x peripheral pain/swelling) + (0.58 x Ln(CRP + 1)); if CRP is not available but ESR is available, the last term is changed by (0.29 x √(ESR)). BASFI:
Bath Ankylosing Spondylitis Functional Index [51] mSASSS: modified Stoke Ankylosing Spondylitis Spine Score [28]
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ment identity, once assigned.
Study population
The study will include subjects with axial spondyloarthritis
treated with anti-TNF for ≥12 weeks who had achieved
sustained clinical remission for 8 additional weeks and who
comply with all inclusion criteria and no exclusion criteria,
as listed in Table 2. Patients may be withdrawn during the
study if they show worsening of the signs or symptoms of
spondyloarthritis requiring anti-TNF treatment modifica-
tion; if anti-TNF treatment interruption is advisable for any
reason; if the planned assessments cannot be made in two
or more scheduled visits; if keeping the patient in the study
may represent a clinical risk, in the physician’s judgement;
or if the patient or their legal representative, in the case of
disability, revokes their consent.
Intervention
The trial will compare two maintenance strategies:
1. Full dose maintenance treatment, according to the
summary of product characteristics and the SER
consensus document on biological therapy for
spondyloarthropathies [27].
2. Reduced dose maintenance treatment according to a
standardized protocol (Table 3).
The strategies will be applied to the anti-TNF agent
the patient is receiving (any anti-TNF drugs currently
available to treat spondyloarthritis). Because the study
will not assign patients to receive a specific drug, but ra-
ther a dosing strategy, the usual clinical dispensation
procedures will not be modified, and therefore, no spe-
cial labelling, masking or medication preparation will be
required. Likewise, the traceability of products will be
the same as in routine clinical practice. In Spain, all
anti-TNF drugs are subject to exclusive and direct dis-
pensation from hospital pharmacies according to a strict
scheme of periodic visits to obtain medication and the
maintenance of a drug supply register.
Visit scheduling and data collection
After confirmation of eligibility and informed consent,
patients will be randomized and prescribed the assigned
treatment. Patients will be seen every 8 weeks, according
to SER- GRESSER recommendations on visit frequency
for patients with spondyloarthritis receiving anti-TNF
[10]. At the baseline visit, weeks 56, 104 and the last
study visit, all parameters required for the assessment of
BASDAI, ASDAS, BASFI, and ASQoL will be obtained
(see Table 1 for definitions). The primary endpoint will
be assessed at visit 8 (week 56 post-inclusion). In all
other visits, patients will undergo the usual clinicalprocedures for disease monitoring according to medical
criteria, information on treatment compliance will be
collected, and patients will be questioned about possible
adverse drug reactions. Plasma and serum samples for
investigation of inflammatory biomarkers and antidrug
antibodies will be collected at the time of clinically indi-
cated routine laboratory testing and at study completion
or withdrawal due to treatment failure, but only from
patients who specifically consent to provide blood sam-
ples. When radiographic evaluation of the spine is indi-
cated as part of routine clinical practice, this will be
recorded in the CRF, in order that a copy may later be
provided for blind assessment of disease progression at
the end of the study (Table 4).
Collaborating sites
This research protocol has received a grant from the Span-
ish Ministry of Health program “Ayudas para el fomento
de la investigación clínica independiente del Ministerio de
Salud, Política Social e Igualdad - Orden SPI/2885/2011,
de 20 de octubre”. Thirty-one Spanish hospitals represent-
ing a wide geographical representation will participate (see
list in Acknowledgements). The trial will be coordinated by
a steering committee formed of five clinical pharmacolo-
gists and five rheumatologists from the lead sites.
Regulatory submissions, ethical submissions, and con-
tracts with sites will be managed by the Clinical Pharma-
cology Service, Hospital Puerta de Hierro (Madrid). The
study will be monitored by the Clinical Trials Unit, Hos-
pital Clínic de Barcelona. A risk-adapted monitoring
plan has been prepared and approved prior to study ini-
tiation. A minimum of two onsite visits will be made for
source data validation of files, informed consent, and key
variables, and ongoing remote monitoring of eCRFs will
be made during the study. A pharmacovigilance plan has
been prepared and approved prior to study initiation,
and tasks will be centralized at the Clinical Pharmacol-
ogy Unit, Hospital de Sabadell. An independent safety
monitoring committee will periodically review data on ser-
ious adverse events and patient withdrawals or discontinu-
ation in order to monitor potential changes in the risk/
benefit of study continuity for participants. No interim
efficacy analysis will be conducted. Biological samples,
clinical operations and study finances will be coordinated
by the Clinical Pharmacology Unit, Hospital de Sabadell.
Sample size calculation
The primary endpoint of the study will be the proportion
of patients compliant with the definition of acceptable
therapeutic goal attainment one year after implementa-
tion of the assigned treatment strategy. Considering the
clinically stable population that the study will enroll, it is
anticipated that no less than 87 % of patients allocated to
the full-treatment arm will meet the clinical remission
Table 2 Eligibility criteria
Inclusion criteria
1. Patients older than 18 years
2. Patients with axial spondyloarthritis according to ASAS group
classification criteria [28], classified as axial spondylitis if either of the two
following sets of conditions is true:
1. Full compliance of A and C, and 1 or more of B OR 2. Full compliance
of A and D, and 2 or more of B
A. Required
criteria
1. Low back pain >3 months duration
2. Age of onset <45 years
B. Clinical criteria 1. Inflammatory low back pain in patients with
chronic low back pain (>3 months), meeting 4 of:
age of onset <40 years
inconspicuous onset
improvement with exercise
no improvement with rest
2. Peripheral arthritis
3. Enthesitis
4. Dactylitis
6. Family history
7. Anterior uveitis
8. Current or previous Crohn’s disease or ulcerative
colitis confirmed by gastroenterologist
9. Current or previous physician-diagnosed
psoriasis
10. HLA-B27
11. Increased CRP
C. Sacroiliitis by
image
1. Sacroiliitis (radiology, MRI): Definite sacroiliitis
according to the modified New York criteria, or
acute inflammation on MRI highly suggestive
of sacroiliitis.
D. Genetic
criteria
1. HLA-B27 positive
3. Previous treatment with an anti-TNF (infliximab, adalimumab,
etanercept, or golimumab) and with sustained clinical remission, as
defined by absence of symptoms and signs of activity spondylitis:
1. BASDAI score less than or equal to 2
2. Absence of clinically active arthritis or enthesitis
3. CRP below or equal to the upper limit of normality, as set by
local laboratory
4. Signed informed consent
Exclusion criteria
1. Patients with secondary spondyloarthritis
2. Patients with spondyloarthritis and predominantly peripheral arthritis,
which have been the leading reason for starting anti-TNF treatment.
3. Patients with spondyloarthritis and any associated pathology known
to impair or affect the clinical assessment (for example, fibromyalgia,
other associated chronic inflammatory diseases)
4. Patients with inflammatory bowel disease
Table 2 Eligibility criteria (Continued)
5. Patients on chronic treatment with anti-TNF therapy who are currently
treated at doses lower than those indicated by the product information.
6. Pregnant or breastfeeding women
ASAS: Assessment of Spondyloarthritis International Society [52] CRP: C-reactive
protein. MRI: magnetic resonance imaging. BASDAI: Bath Ankylosing Spondylitis
Disease Activity Index [49], which is calculated as {A + B + C + D + [(E + F)/2]}/5
where A to E are 6 Visual Analog Scales (VAS) rated 0 (best) to 10 (worst)
assessing (A) fatigue, (B) axial skeletal pain, (C) peripheral joint pain, (D) pain
on contact or pressure, (E) intensity of morning stiffness and (E) duration of
morning stiffness
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with full-dose anti-TNF treatment [30]. Therefore, a sam-
ple size of 85 patients per group would allow the noninfe-
riority of the reduced-dose strategy to be tested with
respect to the full-dose strategy, assuming a noninferiority
margin of 17 % and protection against one-tailed type I
error of 2.5 % and against type II error of 20 % [31, 32].
Statistical analysis
The statistical analysis will be made according to the
principles specified in the International Conference on
Harmonisation (ICH) Topic E9 [33]. A detailed statistical
analysis plan was issued and approved on 25 September
25 2014. The SAS System (SAS Institute Inc., Cary, NC,
USA) v9.2 or upgraded version will be used for the statis-
tical analysis. The alpha level of significance will be set at
0.05 for a two-tailed test.
Mean and standard deviation (SD), least square means
and 95 % confidence intervals (95 % CI) or median and
25 and 75 percentiles (interquartile range: IQR), or as
otherwise specified, will be used for the descriptive ana-
lysis, as appropriate.
Populations for analysis
Three efficacy populations have been prospectively defined:
(a) the randomized set (RS), including all study patients;
(b) the full analysis set (FAS), including all randomized pa-
tients who have effectively met the protocol entry criteria
(as assessed before study entry) and who receive ≥1 dose
of the study treatment; and (c) the per protocol set (PPS)
including patients in the FAS set who comply with the
study treatment without major protocol deviations that
might impact the study’s main assessments. Study devia-
tions will be assessed and documented independently of
the randomization codes during the data blind review prior
to database lock. The PPS is the pre-defined primary popu-
lation for this non-inferiority study. However, the principal
end-point and the key secondary endpoints will also be
tested in the RS and FAS populations for consistency.
Inferential analysis
The principal and key secondary end-points will be
assessed by estimating the between-treatment risk
Table 3 Studied treatments
Drug route Authorized dose in
product information*
Control group Experimental group
(full dose) (reduced dose)
Adalimumab SC 40 mg/2 weeks 40 mg/2 weeks 40 mg/3 weeks
Etanercept SC 25 to 50 mg/3 to 7 days 25 mg/3 or 50 mg/7 days 50 mg/10 days
Golimumab SC 50 mg/month 50 mg/month 50 mg/6 weeks
Infliximab IV 5 mg/kg /6 to 8 weeks 5 mg/kg /6 to 8 weeks 3 mg/kg /8 weeks
*Based on the Summary of Product Characteristics [53–56]
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these against the pre-defined non-inferiority margin (delta
(δ)) of 17 %. If the remission rate of dose reduction is
lower than that of full dose, the lower bound of the confi-
dence interval in the full dose arm has to be above 60 % to
conclude noninferiority, to ensure that the controlTable 4 Summary of study assessments and procedures
V1
d0
V2 +
8w
V3 +
16w
V4 +
24w
V5 +
32w
V6 +
40w
V7 +
48w
Informed consent X
Anamnesis X
Eligibility X
Randomization X
Treatment
regimen
X
Treatment
compliance
X X X X X X
Patient global
assessment
X
Physician global
assessment
X
Axial night pain X
Use of NSAIDs X
BASDAI* X
ASAS X
Lab testing:
CRP, ESR*
X*
ASDAS-C* X*
BASFI X
ASQoL X
Adverse events X X X X X X
Ideal therapeutic
goal *
X
Acceptable
therapeutic goal *
X
Plasma and serum
samples
X+
Imaging (X ray)@ X
See Table 1 for abbreviation and references. *As clinically indicated. For BASDAI and
regardless of whether these are measured at other time points as clinically indicate
@As clinically available according to routine clinical practice. # Last study visit or pa
laboratory testing, and at study completion or withdrawal due to treatment failuretreatment has been reasonably effective. Rates and risk dif-
ferences will be estimated using a log-binomial regression
model including the treatment and the factor used to strat-
ify the assignment. In the event that the model does not
fit, the Poisson link distribution function with robust vari-
ance will be used instead [34–38].V8 +
56w
V9 +
64w
V10 +
72w
V11 +
80w
V12 +
88w
V13 +
96w
V14 +
104w
V15#
last
X X X
X X X X X X X X
X X X
X X X
X X X
X X X
X X X
X X X
X* X* X*
X* X* X*
X X X
X X X
X X X X X X X X
X X X
X X X
X+ X#
X X#
therapeutic goals, they will be always required at visits 8, 14 and 15,
d. Unplanned assessments will be registered in a specific section of the eCRF.
tient withdrawal. +To be collected at the time of clinically indicated routine
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proach and treatments will be compared using the strati-
fied log-rank test; Cox regression models will be used to
estimate hazard risks and their 95 % CI. Gaussian continu-
ous variables with repeated measurements will be analyzed
using mixed models for repeated measurements (MMRM)
[39]. A nonparametric approach for variables with repeated
measurements will use median and IQR as descriptive sta-
tistics and the inferential analysis will be a nonparametric
model based on the MMRM approach, with the dependent
variable rank-transformed and adjustment by stratification
factor. For variables without repeated measurements, the
median (95 % CI) and median differences (95 % CI) ac-
cording to Hodges-Lehmann estimates will be compared
using the Mann–Whitney test [40, 41]. The remaining var-
iables will be analyzed according to the following strategy:
categorical variables will compared using Fisher’s exact test,
continuous Gaussian-distributed variables will be com-
pared using an independent t-test, and ordinal and non-
Gaussian continuous data will be compared using the
Mann–Whitney test.
Overall scale scores and individual items for the eCRF-
recorded scales will be analyzed according to their nature,
and the items/components will be analyzed descriptively.
No inferential analysis will be performed for baseline
comparability. Inferential analyses will be limited to the
efficacy variables, the key safety outcome and the main
adverse events.
Handling of missing data
Patients for whom information on the main efficacy out-
come and key secondary outcome is not available at 1 year
will be imputed to failure, irrespective of the reason for
drop-out. No additional imputations will be conducted
for the remaining secondary endpoints. However, con-
tinuous efficacy variables with repeated measurements
will be analyzed by MMRM. This approach is robust to
the presence of missing at random (MAR) values and
conducts the analysis in all subjects despite the presence
of missing values [39, 42, 43]. No formal imputations will
be made for the remaining variables and the analyses will
be based on the available-data-only approach.
Ethical considerations
This study will be conducted in compliance with the
ethical principles of biomedical research, the Guideline
for Good Clinical Practice of the International Confer-
ence on Harmonization (ICH) [44] and the applicable le-
gislation in Spain. The study has been reviewed and
approved by the Ethics Committee for Clinical Research
of the participating sites (see Additional file 1) and au-
thorized by the Spanish Agency for Medicines and Med-
ical Devices before inclusion of patients. Two relevant
amendments to the protocol have been issued afterstudy approval, relative to changes of sites and investiga-
tors and the collection of plasma and serum samples,
both of which have been reviewed and approved by the
Ethics Committee before implementation. An insurance
policy has been contracted to cover compensation to pa-
tients in the case of injuries, in compliance with the re-
quirements of Spanish Law on clinical trials.
All patients will provide written, informed consent be-
fore any study procedure, after being duly informed of
the nature of their participation, the anticipated risks
and benefits, the fact that participation is voluntary and
may be terminated at their wish at any time without fur-
ther explanation, and the confidentiality and protection
of personal information. In addition, separate informed
consent will be obtained from patients regarding plasma
and serum sampling, storage and utilization for investi-
gational purposes.
Discussion
There is broad evidence on the favorable risk/benefit of
anti-TNF agents for the treatment of axial spondyloarthri-
tis in patients who do not respond to NSAIDs [14]. It
seems plausible to believe that low maintenance doses of
anti-TNF might suffice to control the disease in patients in
remission or with very low inflammatory activity [18–20].
Based on this biological plausibility, empirically based anti-
TNF dose reduction during maintenance treatment is a
common off-label practice in routine patient care, some-
times formally supported by recommendations from scien-
tific societies. It is not based, however, on solid clinical
evidence from randomized trials. The REDES-TNF study
aims to confirm whether the dose-reduction strategy is as
effective and safe as full-dose maintenance strategies, while
reducing the healthcare burden and costs.
The study has several strengths, including the large
number of sites involved and the centrally randomized
design requiring entry of patient data in the eCRF before
randomization, thus minimizing the risk of errors in eligi-
bility and of biases in the randomization process. The eli-
gibility requirements include axial involvement and
remission after induction for at least 8 weeks (2 routine
controls), and applies strict remission criteria - according
not only to clinical symptoms but also to biologic param-
eters (CRP), in order to ensure both disease stability and
sample homogeneity, thus maximizing the sensitivity of
the study in detecting differences between treatments.
The high-level comparison of interventions, which in-
cludes all anti-TNF agents available in Spain during the
study period, is intended to provide testing of the gen-
eral concept behind dose-reduction in a low-intensity in-
flammation setting. The selection of the dose regimens
to be tested in the dose-reduction arm was made ac-
cording to existing recommendations [27] and has been
refined by systematizing the clinical experience of the
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as representative of current off-label clinical practice. In
general, the change to dosage reduction has been made
by increasing the dosing interval by 50 %, except in the
case of infliximab, where - based on previous reports
[24, 27] and clinical experience - a reduction in the dose
per kg while maintaining the dosing interval of 8 weeks
was considered more suitable.
The design of the study is pragmatic, with the inter-
vention limited to random assignation to one of two
dosing options but, otherwise, patient follow-up and as-
sessments are those currently used in routine patient
care. The study treatment is prescribed and dispensed
following routine outpatient procedures. For this reason,
the study results are expected to have high external val-
idity. The choice of a noninferiority design is suitable to
the clinical situation, where a new strategy is now being
applied empirically, and a “saving” therapeutic strategy is
promoted by healthcare payers despite the lack of evi-
dence and of regulatory endorsement in the summary of
product characteristics.
The noninferiority (delta margin) of 17 % was set based
on the consensus on clinical relevance reached by the
rheumatologists involved, who decided that a proportion
of patients with acceptable control <70 % after 1 year
would severely discourage the use of dose-reduction. The
main variable is based on the acceptable therapeutic goal
instead of the optimal therapeutic goal. While complete
resolution of signs and symptoms is a desirable goal, the
definition of acceptable therapeutic goal represents the
degree of residual signs and symptoms that, clinically,
may not merit a change in the therapeutic strategy; thus,
with respect to medical decision making, the acceptable
therapeutic goal is a more useful primary variable than
the optimal therapeutic goal. A thorough assessment of
treatment safety during the study may help to establish a
comparative risk/benefit profile of the two options, which
is a key point in the indication of long-term treatment. Fi-
nally, the collection of biological samples during treat-
ment and when there is disease relapse may serve as a
basis to predict the clinical or biological features of pa-
tients who may be at higher risk of failure, which could
be for future guidance.
Statistically, the choice of the FAS as the primary ana-
lysis set is generally not regarded as conservative [33]
because it is considered that the PP conditions most
closely reflect the scientific model and more reliably rep-
licate the conditions in which active control is likely to
be effective, thus ensuring the sensitivity of the assay.
However, ideally both analyses should have equal im-
portance and should lead to similar conclusions [45].
Therefore, although analysis of the PP set will be the
predefined primary analysis, the principal end-point and
the key secondary end-points will also be tested in theRS and FAS populations. Losses to follow up should be
minimized in order to avoid bias by ensuring that pa-
tients are followed further even if the assigned treatment
strategy is modified. However, continuous efficacy vari-
ables with repeated measurements will be analyzed using
MMRM. This approach is robust to the presence of data
missing at random, and makes the analysis in all subjects
despite missing values. With this method, estimates are
calculated based on the variance-covariance structure
but without any formal imputations.
The primary endpoint was initially intended for ana-
lysis by the Mantel-Haenzel method [46]. However, since
the noninferiority margin was predefined and justified
on clinical grounds using a risk difference scale, we pro-
spectively amended the statistical method to directly ad-
dress testing against the margin on the same scale.
Therefore, noninferiority will be checked by testing the
estimated treatment of the one-sided 97.5 % CI of the
risk difference against the noninferiority margin of 17 %
using a log-binomial regression model as detailed in the
statistical section. The main outcome will also be ana-
lyzed using the Mantel-Haenzel method predefined in
the protocol for sensitivity purposes.
Considering the study operations, the strategies com-
pared, full and reduced dose, are currently considered as
equally appropriate for the treatment of patients with
spondyloarthritis and are widely used. This may repre-
sent a challenge to recruitment because, due to financial
pressures in healthcare, many patients will have already
undergone dose reduction. In fact, one of the main chal-
lenges of the study is to meet the recruitment goal on
time in order to ensure that all patients are assessed for
the main efficacy outcome before study funding ends.
The study has a number of potential limitations. First,
the study is not blinded, since it was thought that the
complexity, costing and risk of medication errors associ-
ated with the use of double dummy (different doses in iv
injections for infliximab, placebo subcutaneous injec-
tions matching the alternative posology for adalimumab,
etanercept and golimumab) did not outweigh the bene-
fits of blinded assessment of outcomes, especially for the
subcutaneous treatments, which would have required an
increase in the number of injections over a long time
period. Likewise, blinded assessors will not be used be-
cause the decision to modify treatment in the event of
clinical flare will mainly be based on the patient’s report-
ing of disease signs and symptoms (BASDAI score and
axial night pain). Therefore, it is expected that if the pa-
tient’s reports are biased due to knowing the identity of
treatment, they will tend to consider the low-dose treat-
ment as less efficacious than the full dose treatment.
Thus, the bias would likely be conservative, contrary to
the main study hypothesis, and reflective of what may be
expected after dose reduction in routine clinical practice.
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NSAIDs and DMARDs will not be standardized and may
be varied by the investigators as required during the study
to control symptoms. While this may be regarded as a
potential source of confusion, the use of these additional
treatments is quantified during the trial and will be ana-
lyzed to determine whether either of the arms is associ-
ated with an increase in the use of concurrent anti-
inflammatory drugs or DMARDs. Third, patients will be
stratified only according to the anti-TNF drug, in order to
maintain a reasonable number of strata. Additional fac-
tors with potential prognostic implications (for example,
time since first diagnosis, use of DMARDs, duration of
clinical remission at randomization) were not considered.
Although these factors have been reported to predict a
clinical response to anti-TNF therapy [47, 48], until now
there is no data on their value in predicting the clinical
result of anti-TNF dose reduction. Fourth, the duration of
follow-up until the main efficacy assessment is limited to
one year. Although this period may be considered a rea-
sonable timeframe in which to test the clinical acceptabil-
ity of each therapeutic option, the study will not be able
to provide information to guide clinical decisions after
this time. Additionally, it is unlikely the study will be able
to detect relevant differences in structural end-points by
spine imaging because changes are generally slower in
axial spondyloarthritis. It is also anticipated that the study
will not be able to detect differences in efficacy or safety
between the dosages of each anti-TNF studied.
In summary, the REDES-TNF study is a pragmatic clin-
ical trial sponsored by two medical scientific societies that
aims to answer the need for evidence to support medical
decisions now taken empirically. The results of the trial
may be useful in guiding the management of patients
with spondyloarthropathies requiring anti-TNF treatment.
Trial status
The trial was first authorized on 3 April 2012, and the
first patient was recruited into the study on July 2012.
The expected date of completion (last visit of last patient)
is end of April 2015.
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